UPDATE - AnPac Bio Commences Proposed Public Offering of American Depositary Shares
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. A registration statement on Form F-3 (File No. 333-256630) relating to the securities was filed with the
The offering is being made only by means of a prospectus supplement and accompany prospectus. A prospectus supplement describing the terms of the public offering will be filed with the
Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting EF Hutton, division of Benchmark Investments, LLC Attention:
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About AnPac Bio
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 148 issued patents as of
For more information, please visit: https://www.AnPacBio.com.
This press release contains statements that constitute “forward-looking statements,” including with respect to the Company’s proposed offering. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus supplement and prospectus for the offering filed with the
For investor and media inquiries, please contact:
Phone: +1-267-810-6776 (US)
Source: Anpac Bio, USA